经验和预后分析使用Avelumab切换维护治疗在转移性尿路细胞癌的经验和预后分析
Teruki Isobe1, Taku Naiki1, Yosuke Sugiyama2
1Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Oncology
|July 2, 2024
概括
在转移性尿路细胞癌患者中,AVELUMAB维持疗法显著改善了整体生存率. 老年营养风险指数的可持续性可以预测这种有效治疗的适合性.
科学领域:
- 在瘤学瘤学.
- 尿癌研究 尿癌研究
- 免疫治疗是一种免疫疗法.
背景情况:
- 艾维卢马布 (Ave) 是已批准用于转移性尿路细胞癌 (mUC) 的维持疗法,证明了延长整体存活率 (OS).
- 了解治疗趋势和确定mUC中Avelumab疗效的预测因素对于优化患者结果至关重要.
研究的目的:
- 为了探索Avelumab治疗mUC患者的趋势.
- 为了比较Avelumab维护治疗的患者与未接受治疗的患者的临床参数和预后.
- 为了确定预后因素,包括老年营养风险指数 (GNRI),用于预测适合Avelumab治疗.
主要方法:
- 从2019年1月到2022年11月接受一线化疗的72名mUC患者的回顾性分析.
- 在Avelumab治疗 (n=43) 和Avelumab未治疗 (n=29) 组之间的临床参数和OS的比较.
- 预后因素的评估,包括GNRI的可持续性,用于识别Avelumab适合的患者,使用接收器运行特征曲线分析.
主要成果:
- 两组之间基线临床参数没有显著差异.
- 与未接受AVELUMAB治疗组 (12.0个月) 相比,适合AVELUMAB的患者的中位寿命显著更长 (26.6个月),并有可管理的不良事件.
- 在单变量和多变量分析中,低年龄和GNRI可持续性被确定为Avelumab适合性的显著预后因素.
结论:
- 维护治疗延长了 mUC 患者的 OS,具有可容忍的安全性.
- GNRI可持续性成为潜在的预测生物标志物,用于识别适合Avelumab维持治疗的患者.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K